Synthesis of zinc oxide based etoricoxib and montelukast nanoformulations and their evaluation through analgesic, anti-inflammatory, anti-pyretic and acute toxicity activities

Abstract

The current study described the synthesis of novel low dose PVA capped Etoricoxib (ET) and montelukast (MT) conjugated Zinc Oxide (ZnO) nanomaterials (NMs) as potential anti-inflammatory, analgesic and antipyretic agents. A facile coprecipitation protocol was used for synthesis of NMs by combination of ET, MT and ZnO NP. The efficient synthesis of ET and MT conjugated ZnO NMs were confirmed through UV–visible, XRD, FTIR and DLS analysis. Data of in vivo anti-inflammatory activity indicated that potency of ZnO NMs was found to be greater than drugs (ET and MT). Analgesic potency of NMs was much higher than that of drugs (ET and MT). The in vivo antipyretic activity indicates that the results of NMs and drugs (ET and MT) are of similar effect but that of NMs are more potent based on per weight basis. A wide therapeutic window was shown by the acute toxicity study carried out via LD50 method. It is concluded that the novel low dose PVA capped ET and MT conjugated ZnO NMs were potential analgesic, antipyretic and anti-inflammatory agents.

Keywords

• Zinc oxide nanoparticles
• Etoricoxib
• Montelukast
• Analgesic activity
• Anti-inflammatory activity
• Anti pyretic activity